Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
18.46
-0.25 (-1.34%)
At close: Mar 28, 2025, 4:00 PM
18.07
-0.39 (-2.11%)
After-hours: Mar 28, 2025, 5:16 PM EDT

Cadrenal Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Selling, General & Admin
6.753.552.52
Research & Development
4.214.080.43
Operating Expenses
10.967.632.95
Operating Income
-10.96-7.63-2.95
Interest Expense
--0.02-0.12
Interest & Investment Income
0.310.250
Other Non Operating Income (Expenses)
--0.22-4.26
EBT Excluding Unusual Items
-10.65-7.62-7.32
Other Unusual Items
--0.74-
Pretax Income
-10.65-8.36-7.32
Net Income
-10.65-8.36-7.32
Net Income to Common
-10.65-8.36-7.32
Shares Outstanding (Basic)
111
Shares Outstanding (Diluted)
111
Shares Change (YoY)
35.59%70.99%-
EPS (Basic)
-8.73-9.29-13.92
EPS (Diluted)
-8.73-9.29-13.92
Free Cash Flow
-7.36-3.53-1.32
Free Cash Flow Per Share
-6.04-3.93-2.50
EBITDA
-10.96-7.63-2.95
D&A For EBITDA
000
EBIT
-10.96-7.63-2.95
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q